Difference between revisions of "Part:BBa K364309:Experience"

 
(Ligand)
 
(6 intermediate revisions by the same user not shown)
Line 1: Line 1:
 
 
__NOTOC__
 
__NOTOC__
 
This experience page is provided so that any user may enter their experience using this part.<BR>Please enter
 
This experience page is provided so that any user may enter their experience using this part.<BR>Please enter
 
how you used this part and how it worked out.
 
how you used this part and how it worked out.
 +
 +
===Ligand===
 +
 +
Estrogens
 +
 +
Estrogens (AmE), oestrogens (BE), or œstrogens, are a group of steroid compounds,
 +
named  for  their  importance  in  the  estrous  cycle,  and  functioning  as  the  primary
 +
 +
female  sex  hormone.  Their  name  comes  from  estrus/oistros  (period  of  fertility  for
 +
female mammals) + gen/gonos = to generate.
 +
 +
Estrogens are synthesized in all vertebrates as well as some insects. The presence
 +
of  these  steroids  in  both  vertebrate  and  insects  suggests  that  estrogenic  sex
 +
hormones have an ancient history.
 +
 +
Estrogens  are  used  as  part  of  some  oral  contraceptives,  in  estrogen  replacement
 +
therapy  for  postmenopausal  women,  and  in  hormone  replacement  therapy  for  trans
 +
women.
 +
 +
Like inside  the  cell,  they  bind  to  and  activate  estrogen  receptors  which  in  turn  modulate
 +
the G protein-coupled receptor, GPR30.
 +
 +
===Physiological effects of ER===
 +
In the absence of hormone, estrogen receptors are largely located in the cytosol. Hormone binding to the receptor triggers a number of events starting with migration of the receptor from the cytosol into the nucleus, dimerization of the receptor, and subsequent binding of the receptor dimer to specific sequences of DNA. Some of the effects in humans: Createing proliferative endometrium,breast cell stimulation, increased body fat and weight gain, salt and fluid retention, increased risk of blood clots.
 +
 +
===Potential applications===
 +
ER LBD can be fused with different DBDs in order to get heterogenous composite nuclear receptors activating gene expression depending on the binding site of the fused DBD.
  
 
===Applications of BBa_K364309===
 
===Applications of BBa_K364309===

Latest revision as of 02:00, 26 October 2010

This experience page is provided so that any user may enter their experience using this part.
Please enter how you used this part and how it worked out.

Ligand

Estrogens

Estrogens (AmE), oestrogens (BE), or œstrogens, are a group of steroid compounds, named for their importance in the estrous cycle, and functioning as the primary

female sex hormone. Their name comes from estrus/oistros (period of fertility for female mammals) + gen/gonos = to generate.

Estrogens are synthesized in all vertebrates as well as some insects. The presence of these steroids in both vertebrate and insects suggests that estrogenic sex hormones have an ancient history.

Estrogens are used as part of some oral contraceptives, in estrogen replacement therapy for postmenopausal women, and in hormone replacement therapy for trans women.

Like inside the cell, they bind to and activate estrogen receptors which in turn modulate the G protein-coupled receptor, GPR30.

Physiological effects of ER

In the absence of hormone, estrogen receptors are largely located in the cytosol. Hormone binding to the receptor triggers a number of events starting with migration of the receptor from the cytosol into the nucleus, dimerization of the receptor, and subsequent binding of the receptor dimer to specific sequences of DNA. Some of the effects in humans: Createing proliferative endometrium,breast cell stimulation, increased body fat and weight gain, salt and fluid retention, increased risk of blood clots.

Potential applications

ER LBD can be fused with different DBDs in order to get heterogenous composite nuclear receptors activating gene expression depending on the binding site of the fused DBD.

Applications of BBa_K364309

User Reviews

UNIQe3e44ba0324acabe-partinfo-00000000-QINU UNIQe3e44ba0324acabe-partinfo-00000001-QINU